While CD19 is an almost ideal tumor associated antigen (TAA), the approval of B-cell maturation antigen (BCMA) CAR-T cell therapies for multiple myeloma confirms that these principles can be transferable [15]. This evidence concerns the gene TNFRSF17 and AL amyloidosis.